Tag: aldafermin

All Podcast Categories
S2-E56 - Day Four at the 2021 TLMdX From AASLD

S2-E56 – Day Four at the 2021 TLMdX From AASLD

Drs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD

S2-E55 - Day Three at the 2021 TLM dX From AASLD

S2-E55 – Day Three at the 2021 TLMdX From AASLD

Profs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.

S2-E42.3 - Why FGFs Matter - Episode Opening and Closing, Plus a Question About Screen Fail Rates

S2-E42.3 – Why FGFs Matter and Screen Fail Rate

Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGFs) agents and why they are so important to the future of NASH and NAFLD therapy. This conversation detours into health policy and screen fail rates before returning to consider the 2-5 year implications of FGF drug therapies.

S2-E42.2 - How FGFs Work In The Body And What This Means For NAFLD And NASH

S2-E42.2 – How FGFs Work In The Body And What This Means For NAFLD and NASH

Professor Arun Sanyal and Stephen Harrison provide a 40-minute briefing on fibroblast growth factor (FGFs) agents and why they are so important to the future of NASH and NAFLD therapy. The roles fibroblast growth factors (FGFs) play in fat metabolism, appetite and other issues related to Fatty Liver disease.

Stay In Touch with Surfing NASH

Stay In Touch
  • Name
  • Email & NPI
  • Country
  • Institution & Profession